Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

ISV-401 safe and effective in acute bacterial conjunctivitis

Oct. 1, 2002

New phase III study for anecortave acetate in AMD

Sep. 5, 2002

Compounds for glaucoma and ocular hypertension with improved profile over natural prostaglandins

Sep. 4, 2002

E.U. approval for Visudyne

Sep. 2, 2002

Subanalysis of SnET2 phase III data

Aug. 29, 2002

Clinical trial commences for squalamine in treatment of AMD

Aug. 23, 2002

VitrenASE enters phase II trial in proliferative vitreoretinopathy

Aug. 21, 2002

InSite Vision and Bausch & Lomb sign agreement for ISV-403 development

Aug. 13, 2002

EyeTech completes enrollment in two pivotal Macugen trials

Aug. 12, 2002

Collagen-derived agent for dry eye syndrome licensed by Santen

July 25, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.